Potential New Therapeutic Approaches for Myelofibrosis

[1]  D. Niederwieser,et al.  Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Mead,et al.  MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. , 2021, Future oncology.

[3]  Kaori Ito,et al.  Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. , 2020, Blood advances.

[4]  A. Mead,et al.  Duration of Response to Luspatercept in Patients (Pts) Requiring Red Blood Cell (RBC) Transfusions with Myelofibrosis (MF) - Updated Data from the Phase 2 ACE-536-MF-001 Study , 2020 .

[5]  S. Verstovsek,et al.  The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis , 2020 .

[6]  P. Trojer,et al.  MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients , 2020, Blood.

[7]  S. Verstovsek,et al.  A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor , 2020 .

[8]  H. Dai,et al.  Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma , 2020 .

[9]  S. Verstovsek,et al.  Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms , 2020, Cancers.

[10]  Angela G. Fleischman,et al.  ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. , 2020, Blood advances.

[11]  S. Verstovsek,et al.  JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives , 2020, HemaSphere.

[12]  R. Mesa,et al.  Management of challenging myelofibrosis after JAK inhibitor failure and/or progression. , 2020, Blood reviews.

[13]  S. Verstovsek,et al.  The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. , 2020, Clinical lymphoma, myeloma & leukemia.

[14]  R. Foà,et al.  Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis , 2019, Cancer.

[15]  H. Kantarjian,et al.  Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis , 2018, European journal of haematology.

[16]  B. Bernstein,et al.  Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. , 2018, Cancer cell.

[17]  H. Kantarjian,et al.  Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. , 2017, Blood.